SOFIE and GE HealthCare SNMMI Symposium highlights FAP targeting
June 9, 2024 (Toronto, CA) – SNMMI annual meeting attendees had the opportunity to learn […]
Trilantic North America Completes Strategic Growth Investment in SOFIE Biosciences
NEW YORK (June 4, 2024) – Trilantic North America, a growth-focused middle market private equity […]
[18F]FAPI-74 serving as complementary diagnostic in Avacta Phase 1 trial
May 23, 2024 – SOFIE is pleased to partner with Avacta through Avacta’s use […]
SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers
- A global licensing agreement has been signed for the development and […]
FAP symposium another success at 2023 SNMMI meeting
June 25, 2023 – For the second year in a row, the spotlight shone on […]
SOFIE partners with BAMF Health, diversifying sites for Phase II [68Ga]FAPI-46 study
SOFIE has added BAMF Health, a novel cancer treatment center in Grand Rapids, Michigan, as […]
First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial
Dulles, VA –May 12, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]